Bioavailability of Dabigatran and Digoxin in Healthy Volunteers

Phase 1, randomised, open-label trial of dabigatran in venous thromboembolism (VTE) and Atrial fibrillation (AFib) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve at steady state over a uniform dosing interval tau and Maximum measured concentration at steady state. Started Jun 2006; status: completed.